| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/08/2007 | US20070032547 Method and device for treating migraine, tension-type and post-traumatic headache, atypical facial pain, and cervical muscle hyperactivity |
| 02/08/2007 | US20070032546 Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
| 02/08/2007 | US20070032545 Antibiotic fki-1778 and process for producing the same |
| 02/08/2007 | US20070032544 Medicinal acidic cannabinoids |
| 02/08/2007 | US20070032543 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients |
| 02/08/2007 | US20070032542 Process for the preparation of enantiopure pyrrolidin-2-one derivatives |
| 02/08/2007 | US20070032541 monocyte chemotactic proteins (MCP)-1 receptor antagonist or agonist; 2-{1-[(1,2-cis)-2-(4-Methylsulfanyl-benzoylamino)-cyclohexyl]-2-oxo-pyrrolidin-3-ylcarbamoyl}-4-trifluoromethyl-phenyl)-carbamic acid tert-butyl ester; antiinflammatory agent, antiallergen; asthma, rheumatoid arthritis, atherosclerosis |
| 02/08/2007 | US20070032540 By reacting indole-4-carboxaldehyde with nitromethane, reducing the nitro group to form an amine, propylating the amine group, oxidizing the 2 C atom in the indole ring, and optionally forming a salt, especially the hydrochloride |
| 02/08/2007 | US20070032538 Use of compounds |
| 02/08/2007 | US20070032537 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases |
| 02/08/2007 | US20070032536 Compounds, compositions and methods |
| 02/08/2007 | US20070032535 Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof |
| 02/08/2007 | US20070032534 12,13-desoxyepothilones, used as anticarcinogenic agents |
| 02/08/2007 | US20070032533 Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use |
| 02/08/2007 | US20070032532 Hsp90 family protein inhibitors |
| 02/08/2007 | US20070032531 Sphingosine kinase inhibitors and methods of their use |
| 02/08/2007 | US20070032530 Phenylpyridine derivatives |
| 02/08/2007 | US20070032529 Pyrazole compounds and their use as antidiabetes agents |
| 02/08/2007 | US20070032528 inhibitors of vascular endothelial growth factor receptor tyrosine kinase; antiproliferative agents; antitumor; 4-Hydroxy-3-(5-methylbenzimidazol-2-yl)hydropyridino[3,4-b]pyridin-2-one; nitrogen containing cyclic compounds |
| 02/08/2007 | US20070032527 Method of inhibiting angiogenesis |
| 02/08/2007 | US20070032526 Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents |
| 02/08/2007 | US20070032525 e.g. (1H-benzoimidazol-2-yl)-[1-(3,4-dichloro-benzyl)-piperidin-4-ylmethyl]-amine; chemokine (C-C motif) receptor antagonist; antiallergen; asthma and allergic rhinitis, atopic dermatitis, urticaria, contact dermatitis, alleriric coniunctivitis, inflammatory bowel disease, AIDS, eosinqphilia |
| 02/08/2007 | US20070032524 Diphenylmethyl compounds useful as muscarinic receptor antagonists |
| 02/08/2007 | US20070032523 Chemical compounds |
| 02/08/2007 | US20070032522 Antiviral agents |
| 02/08/2007 | US20070032521 Use of c-kit inhibitors for treating type II diabetes |
| 02/08/2007 | US20070032520 Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 02/08/2007 | US20070032519 Compounds modulating c-kit and c-fms activity and uses therefor |
| 02/08/2007 | US20070032518 Compounds and methods of use |
| 02/08/2007 | US20070032517 such as N-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide, used as selective antagonists of cannabinoid-1 receptors, useful in the treatment, prevention and suppression of nervous system disorders |
| 02/08/2007 | US20070032516 Use of Tiotropium Salts in the Treatment of Severe Persistent Asthma |
| 02/08/2007 | US20070032515 Anaplastic lymphoma kinase modulators and methods of use |
| 02/08/2007 | US20070032514 2,4-diamino-pyrimidines as aurora inhibitors |
| 02/08/2007 | US20070032513 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide |
| 02/08/2007 | US20070032512 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors |
| 02/08/2007 | US20070032511 Amorphous ziprasidone mesylate |
| 02/08/2007 | US20070032510 Antagonists to treat neurodegenerative diseases like Parkinson's disease; 2,4,6-trisubstituted pyrimidines; N-(2,6-diphenyl-pyrimidin-4-yl)-benzamide |
| 02/08/2007 | US20070032509 New capped pyrazinoylguanidine sodium channel blockers |
| 02/08/2007 | US20070032508 Quinazoline derivatives as tyrosine kinase inhibitors |
| 02/08/2007 | US20070032507 Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug. |
| 02/08/2007 | US20070032506 Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride |
| 02/08/2007 | US20070032505 Crystalline form of gatifloxacin |
| 02/08/2007 | US20070032504 Polymorphic form of 3-phenylsulfonyl -8-piperazin-1-yl-quinoline |
| 02/08/2007 | US20070032503 Method of preparation of azaindole derivatives |
| 02/08/2007 | US20070032502 Quinazoline derivatives useful in cancer treatment |
| 02/08/2007 | US20070032501 Aryl pyridines and methods of their use |
| 02/08/2007 | US20070032500 Therapeutic agents useful for treating pain |
| 02/08/2007 | US20070032499 Novel cysteine protease inhibitors and their therapeutic applications |
| 02/08/2007 | US20070032498 Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species |
| 02/08/2007 | US20070032497 Fused-ring compounds and use thereof as drugs |
| 02/08/2007 | US20070032496 Compounds for the Treatment of Neurodegeneration and Stroke |
| 02/08/2007 | US20070032495 Pyrazolotriazines as kinase inhibitors |
| 02/08/2007 | US20070032494 Thyroid hormone analogs |
| 02/08/2007 | US20070032493 Method for treating B cell regulated autoimmune disorders |
| 02/08/2007 | US20070032492 Cytokine Inhibitors |
| 02/08/2007 | US20070032491 Combination of a glycine/nmda antagonist and a tachykinin nk-1 receptor antagonist for use in the treatment of neurodegeneration |
| 02/08/2007 | US20070032489 Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp) |
| 02/08/2007 | US20070032488 6-Membered aryl and heteroaryl derivatives for treating viruses |
| 02/08/2007 | US20070032487 Inhibitors of phosphatidylinositol 3-kinase |
| 02/08/2007 | US20070032486 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides |
| 02/08/2007 | US20070032485 cholesteryl ester transfer protein (CETP) anatgonists such as 2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester, having improved bioavailability |
| 02/08/2007 | US20070032484 Cathepsin K inhibitors |
| 02/08/2007 | US20070032483 Process for the production of mycophenolate mofetil |
| 02/08/2007 | US20070032482 Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments |
| 02/08/2007 | US20070032481 4-(4-fluoro-phenyl)-2-isopropyl-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidine; treatment or prevention of disease states mediated by 5-HT7 and/or 5-HT2 receptor |
| 02/08/2007 | US20070032480 Treatment of ischemia-induced arrhythmias |
| 02/08/2007 | US20070032479 Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines |
| 02/08/2007 | US20070032478 Thiophene-2-carboxylic acid (4-{3-[(4-morpholin-4-yl-phenylamino)-methylene]-2-oxo-2,3-dihydro-1H-indole-6-carbonyl}-phenyl)-amide for modulating tyrosine kinase signal transduction to regulate, modulate and/or inhibit abnormal cell proliferation |
| 02/08/2007 | US20070032477 Pteridine derivatives useful for making pharmaceutical compositions |
| 02/08/2007 | US20070032476 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 02/08/2007 | US20070032475 Novel compounds useful for bradykinin B1 receptor antagonism |
| 02/08/2007 | US20070032474 Use of a compound of formula 1 for making a pharmaceutical composition |
| 02/08/2007 | US20070032473 Substituted amides and their use as medicaments |
| 02/08/2007 | US20070032472 Reacting a 4-morpholinyl aniline with R-epichlorohydrin; carbonylating to form (a chloromethyloxazolidinone; reacting with potassium phthalimide or aziding; forming free amine with hydrazine hydate, which may be amidated with acetic anhydride; oxazolidinone and 3-chloro-2-hydroxypropyl intermediates |
| 02/08/2007 | US20070032471 Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator |
| 02/08/2007 | US20070032470 Novel phenylcarboxyamides as beta-secretase inhibitors |
| 02/08/2007 | US20070032469 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| 02/08/2007 | US20070032468 Novel thioxanthine derivatives for use as inhibitors of mpo |
| 02/08/2007 | US20070032467 Lowering cholesterol by comprises administering ezetimibe and calcium pitavastatin |
| 02/08/2007 | US20070032466 Drug containing chymase inhibitor as the active ingredient |
| 02/08/2007 | US20070032465 Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha |
| 02/08/2007 | US20070032464 Methods of treating cancers |
| 02/08/2007 | US20070032463 Drug, foods or drinks for ameliorating hyperglycemia |
| 02/08/2007 | US20070032462 Novel methods for the preparation of dhea derivatives |
| 02/08/2007 | US20070032461 1,3 Aclyated 24-keto-vitamin d3 compounds and methods of use thereof |
| 02/08/2007 | US20070032460 Use of voacamine and related compounds in the treatment of malaria |
| 02/08/2007 | US20070032459 Using modulators of the G-protein coupled receptors called endothelial gene differentiation ("Edg") receptors; treating cardiovascular disorders, ischemia, cancer; use of quinoline compounds |
| 02/08/2007 | US20070032458 Compound having activity for inhibiting dioxin toxicity, pharmaceutical composition comprising the compound and method for treating disease resulting from dioxin toxicity using the compound |
| 02/08/2007 | US20070032457 Combination therapy for cancer treatment |
| 02/08/2007 | US20070032456 Modulation of cell death |
| 02/08/2007 | US20070032455 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents |
| 02/08/2007 | US20070032454 Especially phenyl-substituted and having Si-H groups or other functional groups such as vinyl-, chloroethyl-, methacryloyloxy- or glycidyloxypropyl-groups; polymer in which the derivative is used as monomer, a comonomer, or a raw material for a polycondensed material |
| 02/08/2007 | US20070032453 Adjuvant chemotherapy for anaplastic gliomas |
| 02/08/2007 | US20070032452 Blood soluble drag reducing hyaluronic acid |
| 02/08/2007 | US20070032451 Blood soluble drag reducing hyaluronic acid |
| 02/08/2007 | US20070032450 New compositions and methods for the treatment of inflammation |
| 02/08/2007 | US20070032449 Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
| 02/08/2007 | US20070032448 Sugar modified nucleosides as viral replication inhibitors |
| 02/08/2007 | US20070032447 Production of reprogrammed cells with restored potential |
| 02/08/2007 | US20070032446 Gapped 2' modified oligonucleotides |